:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autores principales:	Megumi Iwai, Nakyo Heo, Kentaro Hashimoto, Sayuri Guro, Selina Moy, Anna Spence, Tomasz Wojtkowski, Lauren Benner, Melanie Helmick, Tong Zhu, Brian C. Ferslew
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical and Translational Science
Acceso en línea:	https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70310
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
por: Megumi Iwai, et al.
Publicado: (2025)

First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
por: Tomoki Kojima, et al.
Publicado: (2026)

In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers
por: Megumi Iwai, et al.
Publicado: (2024)

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
por: Katharina Erb‐Zohar, et al.
Publicado: (2024)

New Insights Into Hepatic Impairment (HI) Trials
por: Sebastian Haertter, et al.
Publicado: (2025)

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
por: Martha Gonzalez, et al.
Publicado: (2025)

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
por: Yan‐ou Yang, et al.
Publicado: (2025)

Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
por: Olivier Schueller, et al.
Publicado: (2025)

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
por: Raj Vuppalanchi, et al.
Publicado: (2024)

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist
por: Akihito Ogasawara, et al.
Publicado: (2024)

The index and its prime divisors
por: Wojtkowski, Maciej P.
Publicado: (2024)

Ocean Primary Productivity at OPPWG_0367
por: Morel, André
Publicado: (2003)

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study
por: Akira Koibuchi, et al.
Publicado: (2025)

Oceanography at CTD/bottle station IFREMER_0367
por: IFREMER
Publicado: (2001)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
por: Gerald Chun‐To So, et al.
Publicado: (2025)

On Sequence Groups
por: Lipinski, Zbigniew, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment
por: Wanhong Wu, et al.
Publicado: (2025)

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
por: Mary P. Choules, et al.
Publicado: (2025)

Analysis of Selected Research.
por: Helmick, Aileen
Publicado: (1993)

Analysis of Selected Research.
por: Helmick, Aileen
Publicado: (1994)

Analysis of Selected Research.
por: Helmick, Aileen
Publicado: (1992)

Physiologically Based Pharmacokinetic Modeling of Caffeine in Preterm Neonates: Influence of Renal Function and Impairment on Dosing
por: Nolan Thomas, et al.
Publicado: (2025)

Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment
por: Mason McComb, et al.
Publicado: (2025)

Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
por: Aravind Mittur, et al.
Publicado: (2026)

Are Patrons Ready for "Do-It-Yourself" Services?
por: Helmick, Nancy Larsen
Publicado: (1992)

Letter to the Editor: Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
por: Zanzan Zhao, et al.
Publicado: (2025)

Utilising Non‐Nutritive Sucking in Developmental Language Research: Past, Current and Future
por: Guro S. Sjuls
Publicado: (2025)

Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment
por: Islam R. Younis, et al.
Publicado: (2024)

Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment
por: Sean Regan, et al.
Publicado: (2025)

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
por: Xiaotong Hu, et al.
Publicado: (2024)

Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients with Moderate‐to‐Severe Renal Impairment
por: Apinya Boonpeng, et al.
Publicado: (2024)

Journal of Renal and Hepatic Disorders
Publicado: (2017)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
por: Wei Zhu, et al.
Publicado: (2026)

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease
por: Islam R. Younis, et al.
Publicado: (2025)

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment
por: Ping Fu, et al.
Publicado: (2025)

Vacuum structure of an eight-dimensional $SU(3)$ gauge theory on a magnetized torus
por: Kojima, Kentaro, et al.
Publicado: (2024)

Children’s Guided Participation in Jazz Improvisation
por: Gravem Johansen, Guro
Publicado: (2023)

Preterit Expansion and Perfect Demise in Porteño Spanish and Beyond
por: Nore Fløgstad, Guro
Publicado: (2020)

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy
por: Emiel Leegwater, et al.
Publicado: (2024)

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
por: Gerard Greig, et al.
Publicado: (2026)